-
公开(公告)号：US11884720B2
公开(公告)日：2024-01-30
申请号：US15225423
申请日：2016-08-01
发明人： Tobias Raum , Jonas Anlahr , Julie Bailis , Claudia Blümel , Patrick Hoffmann , Peter Kufer , Elisabeth Nahrwold , Doris Rau
CPC分类号： C07K16/28 , C07K16/2809 , C07K16/30 , C07K2317/31 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/92 , C07K2317/94
摘要： The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human MSLN on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
-
公开(公告)号：US20220251243A1
公开(公告)日：2022-08-11
申请号：US17672546
申请日：2022-02-15
发明人： Peter Kufer , Tobias Raum , Patrick Hoffmann , Roman Kischel , Ralf Lutterbuese , Doris Rau , Paul Adam , Eric Borges , Barbara Hebeis , Susanne Hipp
IPC分类号： C07K16/46 , C07K16/28 , C07K14/705 , A61K39/00
摘要： The present invention relates to a binding molecule which is at least bispecific comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope cluster 3 of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule.
-
公开(公告)号：US20210301017A1
公开(公告)日：2021-09-30
申请号：US17264373
申请日：2019-07-29
摘要： The present invention provides a bispecific antibody construct comprising a first binding domain specifically binding to a target such as CD33 and a second binding domain specifically binding to an effector such as CD3 for use in a method for the treatment of myeloid leukemia, wherein the construct is administered in one or more treatment cycles of more than 14 days applying a step dosing comprising at least two steps, a treatment cycle optionally followed by a period without administration of the construct. Moreover, the invention provides a method for the treatment of myeloid leukemia comprising the administration of a therapeutically efficient amount of such bispecific antibody construct and the use of such bispecific antibody construct for the preparation of a pharmaceutical composition for the treatment of myeloid leukemia.
-
公开(公告)号：US10059766B2
公开(公告)日：2018-08-28
申请号：US14761839
申请日：2014-01-27
发明人： Shouhua Xiao , Zheng Pan , Dineli Wickramasinghe , M. Shawn Jeffries , Chadwick Terence King , Brian Mingtung Chan , Peter Kufer , Ralf Lutterbüse , Tobias Raum , Patrick Hoffmann , Doris Rau , Roman Kischel , Bryan Lemon , Holger Wesche
摘要： The invention provides a bispecific antibody construct comprising a first human binding domain capable of binding to human CDH19 on the surface of a target cell and a second domain capable of binding to human CD3 on the surface of a T cell. Moreover, the invention provides a nucleic acid encoding the antibody construct, a vector comprising the nucleic acid and a host cell transformed or transfected with the vector. Furthermore, the invention provides a process for the production of the bispecific antibody construct, a medical use of the antibody construct and a kit comprising the antibody construct. The bispecific antibody construct may be useful in the treatment of melanoma.
-
公开(公告)号：US09765157B2
公开(公告)日：2017-09-19
申请号：US14815861
申请日：2015-07-31
发明人： Shouhua Xiao , Zheng Pan , Dineli Wickramasinghe , Peter Kufer , Patrick Hoffmann , Tobias Raum , Ralf Lutterbüse , Elisabeth Nahrwold , Claudia Blumel
CPC分类号： C07K16/468 , A61K47/60 , A61K2039/505 , C07K16/28 , C07K16/2809 , C07K16/2896 , C07K16/30 , C07K2317/21 , C07K2317/30 , C07K2317/31 , C07K2317/33 , C07K2317/622 , C07K2317/73 , C07K2319/00
摘要： The present invention provides a bispecific antibody construct comprising a first human binding domain which binds to human CDH19 on the surface of a target cell and a second binding domain which binds a human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising the polynucleotide and a host cell transformed or transfected with the polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of the antibody construct in the treatment of melanoma, and a kit comprising the antibody construct.
-
公开(公告)号：US20240209078A1
公开(公告)日：2024-06-27
申请号：US18251196
申请日：2021-11-08
发明人： Stephanie Everts , Matthias Klinger , Virginie Naegele , Adam Zalewski , Claudia Blümel , Thomas Boehm , Johannes Brozy , Igor D'Angelo , Peter Kufer , Petra Lutterbüse , Markus Muenz , Doris Rau , Tobias Raum , Benno Rattel , Oliver Thomas , Ines Ullrich , Joachim Wahl , Christian Webhofer , Sascha Weidler , Elizabeth Dang Pham , Julie Bailis
CPC分类号： C07K16/28 , A61P35/00 , A61K2039/505 , C07K2317/31 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/565 , C07K2317/92
摘要： The present invention provides multitargeting bispecific antigen-binding molecules characterized by comprising a first and a second bispecific entity each comprising a domain binding to target, a second domain binding to an extracellular epitope of the human and the Macaca CD3ε chain, wherein both bispecific entities are linked to each other by a spacer which spaces apart the first and the second bispecific entity. Moreover, the invention provides a polynucleotide, encoding the multitargeting bispecific antigen-binding molecule, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.
-
公开(公告)号：US20200048357A1
公开(公告)日：2020-02-13
申请号：US16373083
申请日：2019-04-02
发明人： Tobias Raum , Markus Münz , Johannes Brozy , Peter Kufer , Patrick Hoffmann , Matthias Friedrich , Benno Rattel , Pamela Bogner , Andreas Wolf , Cornelius Pompe
IPC分类号： C07K16/28 , A61K39/395 , C12N5/16 , C12N15/63
摘要： The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to BCMA, a second domain binding to an extracellular epitope of the human and/or the Macaca CD3ε chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.
-
公开(公告)号：US10301391B2
公开(公告)日：2019-05-28
申请号：US15422619
申请日：2017-02-02
发明人： Tobias Raum , Markus Münz , Johannes Brozy , Peter Kufer , Patrick Hoffmann , Matthias Friedrich , Benno Rattel , Pamela Bogner , Andreas Wolf , Cornelius Pompe
摘要： The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to BCMA, a second domain binding to an extracellular epitope of the human and/or the Macaca CD3ε chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.
-
公开(公告)号：US20170122947A1
公开(公告)日：2017-05-04
申请号：US15313136
申请日：2015-05-20
发明人： Gerhard Zugmaier , Peter Kufer , Shilpa Alekar
IPC分类号： G01N33/574 , A61K35/17 , A61K38/17 , C07K16/28
CPC分类号： G01N33/57426 , A61K35/17 , A61K38/1774 , A61K2035/124 , C07K16/2803 , C07K16/2809 , C07K2317/31 , C07K2317/622 , G01N33/5091 , G01N2333/70503 , G01N2800/50 , G01N2800/52 , G01N2800/56
摘要： The present invention relates to a method for risk-stratifying subjects suffering from B-precursor acute lymphoblastic leukemia (ALL), wherein said subjects are intended for a therapy comprising administration of a CD3 binding domain. Risk-stratification is based on the determination of the amount blast cells in a bone marrow sample from said subject, and/or on the determination of the number of blast cells per 1 μl in a CSF sample from said subject. According to the category into which subjects are risk-stratified, said subjects can be appropriately treated, while their risk of a potential adverse neurological reaction can be reduced or even excluded.
-
公开(公告)号：US20170029502A1
公开(公告)日：2017-02-02
申请号：US15225423
申请日：2016-08-01
发明人： Tobias Raum , Jonas Anlahr , Julie Bailis , Claudia Blümel , Patrick Hoffmann , Peter Kufer , Elisabeth Nahrwold , Doris Rau
IPC分类号： C07K16/28
CPC分类号： C07K16/28 , C07K16/2809 , C07K16/30 , C07K2317/31 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/92 , C07K2317/94
摘要： The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human MSLN on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
摘要翻译： 本发明涉及双特异性抗体构建体，其包含与靶细胞表面上的人MSLN结合的第一结合结构域和与T细胞表面上的人CD3结合的第二结合结构域。 此外，本发明提供编码抗体构建体的多核苷酸，包含所述多核苷酸的载体和用所述多核苷酸或载体转化或转染的宿主细胞。 此外，本发明提供了制备本发明的抗体构建体的方法，所述抗体构建体的医学用途和包含所述抗体构建体的试剂盒。
-
-
-
-
-
-
-
-
-
搜索结果
90 条记录 (耗时 0.036 秒)
